esmo 2020 highlights on durability of clinical benefit and biomarkers with amg510 in nsclc
Published 4 years ago • 1.4K plays • Length 3:04Download video MP4
Download video MP3
Similar videos
-
10:09
esmo 2020 expert video report on long term ici outcomes in lung cancer
-
2:39
esmo 2020 highlights on 1st line lorlatinib for alk nsclc: the crown study
-
2:12
esmo 2020 highlights on adjuvant osimertinib for egfr mutated nsclc: the adaura study
-
3:21
esmo 2020 highlights on pembrolizumab as 1st line therapy for auc: the keynote-361 study
-
35:16
highlights from esmo 2020
-
1:02:24
esmo 2020 lung cancer highlights
-
0:58
introducing the esmo magnitude of clinical benefit scale
-
3:35
#esmo22 highlights on actionable inflammatory axis for air pollution induced nsclc
-
2:57
esmo 2020 highlights on lenvatinib plus pembrolizumab in advanced solid tumours: leap-005
-
6:37
highlights from esmo 2020 in gynecological cancers
-
2:30
#esmo22 highlights on first-line atezolizumab in nsclc not eligible for platinum: the ipsos study
-
5:20
esmo biomarker factsheets: a pathologist’s perspective
-
3:49
esmo highlights: genitourinary cancers
-
3:11
esmo 2020 highlights on pembrolizumab in la-hnscc: the gortec 2015-01 “pembrorad” study
-
1:06
lung cancer highlights from esmo 2022
-
33:07
esmo 2020: lung cancer latest
-
0:36
esmo 2019 daily reporter - editor's picks: lung cancer